• ISSCR Comments on Reports of Chinese Scientists Performing Genome-Editing During Fertility Treatment

  • 26 November, 2018

    • Reports indicate that scientists in China have used CRISPR-mediated genome editing during in vitro fertilization to modify the genetic material of two embryos that were subsequently implanted into a patient, leading to the birth of two babies. As ISSCR and a number of other organizations have previously stated, the use of nuclear genome editing technologies, such as CRISPR, during fertility treatment is premature and should not be attempted at this time.
    Full story

  • ISSCR Comments to FDA Regarding ClinicalTrials.gov

  • 21 November, 2018

    • In a letter to the U.S. Food and Drug Administration (FDA), the ISSCR commented on proposed industry guidance for "Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank."
    Full story

  • ISSCR Applauds FDA, FTC for Holding Deceptive Stem Cell Clinics Accountable

  • 16 November, 2018

    • The U.S. Food and Drug Administration has issued a warning letter to StemGenex of San Diego after an investigation found its cellular therapy does not conform with good manufacturing practice requirements, is being illegally marketed to treat conditions for which it has not been proven safe or effective, and is putting patients at risk.
    Full story

  • ISSCR Comments on Horizon Europe

  • 2 October, 2018

    • The ISSCR has responded to the European Commission proposal and the European Parliament's amendments for Horizon Europe, the seven-year research and innovation funding program to follow Horizon 2020.
    Full story

  • ISSCR Responds to U.S. Department of Health and Human Services Decision Regarding Fetal Tissue Research

  • 27 September, 2018

    • The ISSCR is troubled by the HHS decision to “conduct a comprehensive review of all fetal tissue research.” The directive appears to come after intensive lobbying efforts by special interest groups with the goals of delaying or curtailing scientific research that relies on fetal tissue.
    Full story

  • ISSCR Opposes Proposal to Restrict Fetal Tissue Research

  • 14 June, 2018

    • 6/14/2018 2:00:00 PM

    The ISSCR opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released a statement on the issue.
    Full story

  • ISSCR Responds to President Trump Signing 'Right to Try' Law

  • 4 June, 2018

    • 6/4/2018 4:00:00 AM

    The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
    Full story

  • ISSCR Applauds Federal Injunctions Against Stem Cell Clinics

  • 10 May, 2018

    • The ISSCR is pleased that federal prosecutors in the U.S. have taken action to halt the marketing and delivery of unproven stem cell treatments at clinics they allege are operating outside of FDA regulation.
    Full story

  • 'Right to Try' Legislation in U.S. House of Representatives is Narrowly Defeated; ISSCR Opposed

  • 12 March, 2018

    • The legislation would have put patients at risk, slowed the development of effective stem cell therapies, and blocked the Food and Drug Administration (FDA) from access to crucial data about the safety and effectiveness of new medical treatments.
    Full story

  • ISSCR 2018 Election Results

  • 12 March, 2018

    • The ISSCR is pleased to announce the results of its 2018 leadership election. On behalf of all members, we extend congratulations to newly-elected officers and board members.
    Full story

  • ISSCR Releases Guidebook to Evaluate Cell Therapy Trials

  • 15 February, 2018

    • The ISSCR is pleased to announce the release of “Stem Cell Based Clinical Trials: Practical Advice for Physicians and Ethics / Institutional Review Boards,“ a guidebook providing background and fundamental questions for clinicians and review boards to ask when considering running or reviewing early phase, cell-based clinical trials. The guide was developed by practicing physician-scientists and stem cell professionals on the ISSCR’s Clinical Translation Committee.
    Full story

  • ISSCR Members Asked to Vote for Future Leaders

  • 17 January, 2018

    • The election is open for several ISSCR leadership posts, and members and trainee members are eligible to cast ballots in the election. Voting closes 5 February, 2018.
    Full story

  • ISSCR Announces Two New Science Communications & Education Managers

  • 4 January, 2018

    • The ISSCR has selected Christopher Barry, PhD, and Julie Perlin, PhD, to be Science Communications & Education Managers, beginning 3 January, 2018.
    Full story

  • ISSCR Announces New Policy Director, Eric Anthony

  • 11 December, 2017

    • The ISSCR has named Eric Anthony to be its new Director of Policy. Anthony served more than eight years as staff in the U.S. Congress, most recently as legislative director for Congresswoman Rosa DeLauro of Connecticut. He will join the Society in early January 2018.
    Full story

  • The ISSCR Remembers Ihor Lemischka

  • 8 December, 2017

    • The ISSCR joins the stem cell community in expressing sadness at the passing of Ihor Lemischka, PhD, Professor of Developmental and Regenerative Biology, Pharmacology and Systems Therapeutics at the Icahn School of Medicine.
    Full story

  • Celebrating Stem Cell Awareness Day, 11 October, 2017

  • 10 October, 2017

    • Each year, Stem Cell Awareness Day is an opportunity to reflect on the scientific advances and discoveries that are rapidly moving the field forward, with implications for the future of regenerative medicine and human health.
    Full story

  • ISSCR Responds to FDA Announcement of Enforcement Direction for Stem Cell Treatments

  • 28 August, 2017

    • The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, to provide “bright lines and appropriate oversight” for regulating stem cell treatments and regenerative medicine.
    Full story

  • ISSCR Congratulates Heather Rooke on New Role

  • 28 August, 2017

    • The ISSCR Scientific Director, Heather Rooke, has accepted a position at Harvard University, and will be leaving the ISSCR on 12 September.
    Full story

  • ISSCR Comments on U.S. Study to Correct Disease Genes in Human Embryos

  • 2 August, 2017

    • A study on the first use of CRISPR technology in the U.S. to correct a disease-causing genetic defect in early stage human embryos.
    Full story
    View All ISSCR News